Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753366 | 1.00 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1754813 | 1.00 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10067862 | 1.00 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1753364 | 1.00 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10107562 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL14205016 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1753486 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1754825 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1753436 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1754839 | 0.92 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| WO-2008049806-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | PNLIP, APOB, LIPC | OPRM1 2897/4885OPRD1 2446/4885OPRK1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.